CompletedPhase 1NCT03800173
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
Studying Marburg hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioCryst Pharmaceuticals
- Principal Investigator
- Daniel Dickerson, MD, PhDPRA Health Sciences
- Intervention
- galidesivir(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2018 – 2019
Study locations (1)
- PRA Health Sciences, Lenexa, Kansas, United States
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03800173 on ClinicalTrials.govOther trials for Marburg hemorrhagic fever
Additional recruiting or active studies for the same condition.